111 / 144
391
[Neuroimágenes en enfermedad de Parkinson: Rol de la resonancia magnética, el SPECT y el PET -Dr. Carlos Juri C. y col.]
the differential diagnosis of Parkinson and tremor
syndromes: A critical assessment of 125 cases. J Neurol.
2011;258(12):2147–54.
46. Juri C, Chana P, Kramer V. Imaging Nigrostriatal Dopaminergic
Deficit in Holmes Tremor with 18F-PR04. MZ-PET/CT. Clin
Nucl Med. 2015;40(9):740–1.
47. Stoessl AJ. Developments in neuroimaging: Positron emission
tomography. Park Relat Disord. 2014;20(SUPPL.1).
48. Peng S, Doudet DJ, Dhawan V, Ma Y. Dopamine PET imaging
and parkinson disease. PET Clin. 2013;8(4):469–85.
49. Brooks DJ, Tambasco N. Imaging synucleinopathies. Mov
Disord. 2016;00(00):n/a – n/a.
50. Eckert T, Sailer M, Kaufmann J, Schrader C. Differentiation
of idiopathic Parkinson’s disease, multiple system atrophy,
progressive supranuclear palsy, and healthy controls using
magnetization transfer imaging. Neuroimage. 2004;21:229–
35. 51.
Whone AL, Watts RL, Stoessl AJ, Davis M,
Reske S, Nahmias C, et al. Slower progression of Parkinson’s
disease with ropinirole versus levodopa: The REAL-PET study.
Ann Neurol. 2003;54(1):93–101.
52. Weingarten CP, Sundman MH, Hickey P, Chen N. Neuroscience
and Biobehavioral Reviews Neuroimaging of Parkinson ’ s
disease : Expanding views. Neurosci Biobehav Rev. Elsevier
Ltd; 2015;59:16–52.
53. Vlaar AMM, van Kroonenburgh MJPG, Kessels AGH, Weber
WEJ. Meta-analysis of the literature on diagnostic accuracy of
SPECT in parkinsonian syndromes. BMC Neurol. 2007;7:27.
54. Djang DSW, Janssen MJR, Bohnen N, Booij J, Henderson
TA, Herholz K, et al. SNM Practice Guideline for Dopamine
Transporter Imaging with 123I-Ioflupane SPECT 1.0. J Nucl
Med. 2012;53(1):154–63.
55. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W,
et al. MDS clinical diagnostic criteria for Parkinson’s disease.
Mov Disord. 2015;30(12):1591–601.
56. Juri C, Viviani P, Chana P. Features associated with the
development of non-motor manifestations in Parkinson’s
disease. Arq Neuropsiquiatr. 2008;66(1):22–5.
57. Politis M, Niccolini F. Serotonin in Parkinson’s disease. Vol.
277, Behavioural Brain Research. 2015. p. 136–45.
58. Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT
radioligands for human brain imaging with PET and SPECT.
Med Res Rev. 2013;33(1):54–111.
59. Varrone A, Svenningsson P, Marklund P, Fatouros-Bergman
H, Forsberg A, Halldin C, et al. 5-HT1B receptor imaging
and cognition: a positron emission tomography study in
control subjects and Parkinson’s disease patients. Synapse.
2015;69(7):365–74.
60. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al.
Staging of serotonergic dysfunction in Parkinson’s Disease: An
in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40(1):216–
21.
61. Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1:
Treatment of Levodopa-Induced Dyskinesia. Drugs. Springer;
2016;1–19.
62. Perez-Lloret S, Barrantes FJ. Deficits in cholinergic
neurotransmission and their clinical correlates in
Parkinson’s disease. npj Park Dis. Nature Publishing Group;
2016;2(September 2015):16001.
63. Bohnen N, Kaufer D. Cortical cholinergic function is more
severely affected in parkinsonian dementia than in Alzheimer
disease: an in vivo positron emission tomographic study. Arch
Neurol. 2003;1745–8.
64. Müller M, Bohnen N. Cholinergic dysfunction in Parkinson’s
disease. Curr Neurol Neurosci Rep. 2013;13:1–9.
65. Weingarten CP, Sundman MH, Hickey P, Chen N kuei.
Neuroimaging of Parkinson’s disease: Expanding views.
Neurosci Biobehav Rev. Elsevier Ltd; 2015;59:16–52.
66. Kuhl D, Minoshima S. In vivo mapping of cholinergic terminals
in normal aging, Alzheimer’s disease, and Parkinson’s disease.
Ann Neurol. 1996;399–410.
67. Brooks DJ. Inflammation in Parkinson’s Disease: Scientific
and Clinical Aspects. In: Thomas M, editor. Cham: Springer
International Publishing; 2014. p. 205–16.
68. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers
A, et al. In vivo imaging of microglial activation with [11C]
(R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol
Dis. 2006;21(2):404–12.
69. Klein H., de Witte L, Bransfield RC, De Deyn PP. PET Imaging
of Microglia Activation in Neuropsychiatric Disorders with
Potential Infectious Origin. In: PET and SPECT in Neurology.
2014. p. 739–56.
70. Poston KL, Eidelberg D. FDG PET in the Evaluation of
Parkinson’s Disease. PET Clin. 2010;5(1):55–64.
71. Bohnen NI, Koeppe R a, Minoshima S, Giordani B, Albin
RL, Frey K a, et al. Cerebral glucose metabolic features of
Parkinson disease and incident dementia: longitudinal study.
J Nucl Med. 2011;52(6):848–55.
72. Niethammer M, Feigin A, Eidelberg D. Functional
neuroimaging in Parkinson’s disease. Cold Spring Harb
Perspect Med. 2012;2(5).
73. Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal
metabolic networks in atypical parkinsonism. Mov Disord.
2008;23(5):727–33.
74. Tang CC, Poston KL, Dhawan V, Eidelberg D. Abnormalities
in metabolic network activity precede the onset of
motor symptoms in Parkinson’s disease. J Neurosci.
2010;30(3):1049–56.
75. Yoshita M. Value of MIBG in the Differential Diagnosis of
Neurodegenerative Disorders. In: PET and SPECT in Neurology.
Springer Berlin Heidelberg; 2014. p. 437–49.
76. Lehéricy S, Sharman MA, Santos CL Dos, Paquin R, Gallea
C. Magnetic resonance imaging of the substantia nigra in
Parkinson’s disease. Mov Disord. 2012;27(7):822–30.
77. Mahlknecht P, Hotter A, Hussl A, Esterhammer R, Schocke
M, Seppi K. Significance of MRI in diagnosis and differential
diagnosis of Parkinson’s disease. Vol. 7, Neurodegenerative
Diseases. 2010. p. 300–18.